INVITATION TO PRESENTATION OF FOURTH QUARTER 2015 FINANCIAL RESULTS

NattoPharma will release its fourth quarter 2015 financial results on Friday 26
February 2016 at approximately 08:30 CET. The fourth quarter 2015 report and
presentation will be made available at www.nattopharma.com and at
www.oslobors.no. The same day, starting at 10:00 am, the company will host a
webcast with a presentation of the quarterly results, followed by an online Q&A
session.

Please follow the below link to join the web-cast,

http://webtv.hegnar.no/presentation.php?webcastId=29501855

The presentation will be held by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy.

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

Mobil: +47 906 12 943

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D.
NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK
-7, the best documented, commercially available Vitamin K2 as MK-7 with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements. With a global presence, the company established its North American
subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit www.nattopharma.com or www.Menaq7.com